IRIS
CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.819
EU - Europa 4.826
AS - Asia 1.609
AF - Africa 127
Continente sconosciuto - Info sul continente non disponibili 12
SA - Sud America 2
OC - Oceania 1
Totale 15.396
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.812
UA - Ucraina 1.359
IE - Irlanda 693
SE - Svezia 600
TR - Turchia 591
IT - Italia 573
DE - Germania 571
DK - Danimarca 540
SG - Singapore 473
FI - Finlandia 311
KR - Corea 280
CN - Cina 238
GB - Regno Unito 132
CI - Costa d'Avorio 97
MA - Marocco 29
BE - Belgio 28
IN - India 17
EU - Europa 12
FR - Francia 7
NL - Olanda 6
CA - Canada 5
HK - Hong Kong 4
MX - Messico 2
PH - Filippine 2
RS - Serbia 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BR - Brasile 1
CH - Svizzera 1
ID - Indonesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PL - Polonia 1
TW - Taiwan 1
VN - Vietnam 1
Totale 15.396
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.397
Fairfield 1.029
Chandler 756
Dublin 693
Boardman 670
Wilmington 548
Ashburn 526
Woodbridge 428
Houston 384
Seattle 366
San Mateo 282
Lawrence 280
Princeton 280
Cambridge 274
New York 263
Ann Arbor 222
Centro 212
Des Moines 139
Singapore 136
San Diego 124
Abidjan 97
Beijing 58
Turin 46
Helsinki 33
London 28
Milan 26
Brussels 23
Marche 22
Norwalk 22
Kilburn 20
Guangzhou 16
Izmir 15
Shanghai 15
Los Angeles 14
Pune 14
Washington 14
Dallas 11
Hounslow 11
Wuxi 10
Jiaxing 9
Ancona 8
Acton 7
Prescot 7
Wuhan 7
Yiwu 7
Auburn Hills 6
Hanover 6
Rome 6
Hangzhou 5
New Bedfont 5
Porto 5
Chicago 4
Fayetteville 4
Jinhua 4
Santa Clara 4
Venice 4
Waanrode 4
West Jordan 4
Berlin 3
Chiswick 3
Clifton 3
Florence 3
Montréal 3
Mountain View 3
San Giuliano Terme 3
Sassari 3
Simi Valley 3
Amsterdam 2
Bologna 2
Chongqing 2
Como 2
Dalian 2
Filottrano 2
Foshan 2
Gandosso 2
Heze 2
Isola della Scala 2
Leipzig 2
Montesilvano 2
Montesilvano Marina 2
Nanjing 2
Nantong 2
Palermo 2
Quanzhou 2
Rapagnano 2
Redmond 2
Roseto degli Abruzzi 2
Shenzhen 2
Tlalpan 2
Wandsworth 2
Alameda 1
Andover 1
Bari 1
Belgrade 1
Bellaria-Igea Marina 1
Brasília 1
Buffalo 1
Chizhou 1
Civitanova Marche 1
Cupra Marittima 1
Totale 9.693
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 188
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 160
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 121
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 105
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 104
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy 103
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. 101
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 100
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 98
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 98
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. 97
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 96
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 93
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 93
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 93
Progress of molecular targeted therapies for advanced renal cell carcinoma. 92
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 90
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 89
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 89
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 87
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 86
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 86
Cancer of pancreas. 85
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 85
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 84
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 83
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 83
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 83
New target therapies in advanced pancreatic cancer. 81
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 81
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 81
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 81
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 80
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. 80
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 79
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 78
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 78
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 78
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. 78
Transient sunitinib resistance in gastrointestinal stromal tumors. 78
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 77
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 77
A cost-benefit analysis of chemotherapy for gastric cancer. 76
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. 76
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 76
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 75
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 75
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. 74
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 73
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 73
Metabolic alterations in renal cell carcinoma 72
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 72
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. 71
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. 70
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. 70
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. 70
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. 70
c-erbB-2 and common prognostic factors in breast cancer patients. 70
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 70
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 70
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 69
Panitumumab for the treatment of metastatic colorectal cancer: A review 69
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 69
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 69
Trattamento del carcinoma del pancreas. Attualità e prospettive 68
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 68
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Protein in Urothelial Cell Carcinoma of Human Bladder 67
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 67
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. 66
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 66
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. 66
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 66
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 66
Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. 65
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 65
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 65
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. 65
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 65
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 65
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 65
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. 64
Gastric cancer: Therapeutic choices in advanced disease 64
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 64
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 63
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. 63
Essential role of Gli proteins in glioblastoma multiforme. 62
Insulin-like Growth Factor (IGF) 1 and 2 help to predict disease outcome in GIST patients 61
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 61
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 61
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 61
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 61
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 61
Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. 60
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 60
Locoregional treatments of unresectable liver metastases from colorectal cancer. 60
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. 60
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. 59
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. 59
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 59
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 59
Totale 7.735
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.949
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.589 0 6 272 6 285 1 283 8 282 18 32 396
2020/20214.054 203 479 579 92 500 283 404 265 360 318 375 196
2021/20221.938 113 525 16 69 19 147 72 128 131 208 129 381
2022/20232.719 310 301 215 168 191 323 3 123 839 13 182 51
2023/20241.739 328 31 73 352 321 326 35 34 0 27 15 197
2024/2025725 387 338 0 0 0 0 0 0 0 0 0 0
Totale 15.558